WELCOME TO The Biotechnology REPORT
Trans Ova Genetics
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cytiva, Pall Corporation | June 02, 2021
Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall.
"PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danahe...
PR Newswire | July 22, 2020
Today the K-cosmeceutical company Dermafirm USA, Inc., the U.S. arm of South Korea's Dermafirm Inc., is officially announcing its U.S. expansion. Plans are to formally introduce its U.S. leadership team on July 28th, at a private, virtual event. During the event, the company will kick off a movement with a mission to embrace scientific innovation, educate consumers on clean, natural and healthy DIY skincare options and ultimately empower users to perform these skincare regimens safely at hom...
Quantum Genomics | December 06, 2021
Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey.
A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...
CELL AND GENE THERAPY
Astellas Pharma Inc. and Dyno Therapeutics, Inc. | December 02, 2021
Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform.
Dyno's CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create novel AAV capsids – the cell-targeting protein shells of viral vectors...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE